Abstract
The immunosuppressive drug regimen most commonly used for kidney transplant recipients during the last 10 years was a combination of cyclosporine with either steroids or azathioprine, or both. More recently, new immunosuppressive drugs, such as tacrolimus, mycophenolate and rapamycin have been introduced and hopes were raised that these new medications would improve the success rate of kidney grafts. Experience with these new drugs is still limited and long-term follow up is currently not available. The present report provides an overview of results obtained with regimens that were considered `standard’ during the last 10 years. They should serve as a reference against which future improvements can be measured.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Editor information
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Opelz, G., Döhler, B., Wujciak, T. (1999). Current results as reference for future improvements in immunosuppression. In: Cochat, P., Traeger, J., Merieux, C., Derchavane, M. (eds) Immunosuppression under Trial. Transplantation and Clinical Immunology, vol 31. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4643-2_1
Download citation
DOI: https://doi.org/10.1007/978-94-011-4643-2_1
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-5960-2
Online ISBN: 978-94-011-4643-2
eBook Packages: Springer Book Archive